PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary OpGen Receives Regulatory Approval to Market Pathogen Identification Products in Colombia
Approval gives OpGen its first commercial product in the region; paves way for broader expansion into South American markets GAITHERSBURG, Md. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today it has received approval from the Instituto Nacional de Vigilancia de
View HTML
Toggle Summary OpGen Reports third quarter 2018 Financial Results and Provides Business Update
Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today reported financial and operating results for the three and nine months ended September 30, 2018 and provided a business update.
View HTML
Toggle Summary OpGen Completes Specimen Accrual and Testing in Acuitas® Clinical Verification Study
Study evaluated potential utility in management of complicated urinary tract infections; Analysis and peer-reviewed manuscript preparation are underway GAITHERSBURG, Md. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced it has completed specimen accrual and testing of
View HTML
Toggle Summary OpGen Announces Date of Third Quarter 2018 Financial Results Conference Call
GAITHERSBURG, Md. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced that the Company will report financial results for the three and nine months ended September 30, 2018 after the close of the U.S. financial markets on Tuesday, November 13, 2018 .
View HTML
Toggle Summary OpGen Collaborates With QIAGEN to Advance Rapid Diagnostics for Antimicrobial Resistant Bacteria
GAITHERSBURG, Md. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced a collaboration with QIAGEN N.V. to advance rapid diagnostics for antimicrobial resistance (AMR). Strengthening OpGen’s entry into the United States market, the companies have entered into an agreement
View HTML
Toggle Summary OpGen Announces Pricing of Public Offering of Common Stock
GAITHERSBURG, Md. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced the pricing of an underwritten public offering of approximately 2.2 million shares of its common stock at a public offering price of $1.45 per share. The company has also granted to the underwriters a
View HTML
Toggle Summary OpGen Announces Proposed Public Offering of Common Stock
GAITHERSBURG, Md. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced that it has commenced an underwritten public offering of its common stock. All of the shares are being offered by OpGen, Inc. The offering is subject to market and other conditions, and there can be no
View HTML
Toggle Summary OpGen Provides Business and Preliminary Financial Update
GAITHERSBURG, Md. , Oct. 15, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today provided an update on its commercial activities and clinical trials for its Acuitas® AMR Gene Panel tests and the Acuitas Lighthouse® Software. Preliminary unaudited results for the third quarter of 2018 were
View HTML
Toggle Summary OpGen to Present at Two Upcoming Investment Conferences in October
GAITHERSBURG, Md. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announced today that Evan Jones , Chairman and Chief Executive Officer, will present a corporate overview at two upcoming investment conferences, as follows: Ladenburg Thalmann 2018 Healthcare Conference   Date and
View HTML
Toggle Summary OpGen Partnering with New York State Department of Health and Merck’s ILÚM Health Solutions to Detect Antimicrobial-Resistant Infections
Collaboration with NY Department of Health’s Wadsworth Center to utilize OpGen’s Acuitas AMR Gene Panel u5.47 and Acuitas Lighthouse Software within Statewide digital health and precision medicine platform at healthcare institutions statewide GAITHERSBURG, Md. , Sept.
View HTML